- Home
- ANIX vs ACRS Comparison
ANIX vs ACRS Comparison
Compare ANIX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ACRS
- Stock Information
- Founded
- ANIX 1982
- ACRS 2012
- Country
- ANIX United States
- ACRS United States
- Employees
- ANIX N/A
- ACRS N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- ACRS Health Care
- Exchange
- ANIX Nasdaq
- ACRS Nasdaq
- Market Cap
- ANIX 101.4M
- ACRS 84.2M
- IPO Year
- ANIX 1987
- ACRS 2015
- Fundamental
- Price
- ANIX $3.08
- ACRS $1.21
- Analyst Decision
- ANIX Strong Buy
- ACRS Hold
- Analyst Count
- ANIX 2
- ACRS 5
- Target Price
- ANIX $8.50
- ACRS $1.00
- AVG Volume (30 Days)
- ANIX 42.0K
- ACRS 233.0K
- Earning Date
- ANIX 10-29-2024
- ACRS 11-04-2024
- Dividend Yield
- ANIX N/A
- ACRS N/A
- EPS Growth
- ANIX N/A
- ACRS N/A
- EPS
- ANIX N/A
- ACRS N/A
- Revenue
- ANIX N/A
- ACRS $32,015,000.00
- Revenue This Year
- ANIX N/A
- ACRS N/A
- Revenue Next Year
- ANIX N/A
- ACRS N/A
- P/E Ratio
- ANIX N/A
- ACRS N/A
- Revenue Growth
- ANIX N/A
- ACRS 2.72
- 52 Week Low
- ANIX $2.15
- ACRS $0.59
- 52 Week High
- ANIX $5.13
- ACRS $5.71
- Technical
- Relative Strength Index (RSI)
- ANIX 41.08
- ACRS 56.20
- Support Level
- ANIX $2.95
- ACRS $1.15
- Resistance Level
- ANIX $3.11
- ACRS $1.22
- Average True Range (ATR)
- ANIX 0.12
- ACRS 0.03
- MACD
- ANIX -0.01
- ACRS 0.00
- Stochastic Oscillator
- ANIX 19.35
- ACRS 90.00
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.